Exploring HSP90α and hs-CRP using AI models to predict prognosis in advanced hepatocellular carcinoma treated with PD-1 inhibitors and targeted therapy
Zhen-Ying Wu, Xueting Li, Lu Yang, Yuhui Shi, Xianguo Liu, Lianbin Wen, Yanqiong Song, Wanyun Du, Yulin Tu, Qian Wei, Junqi Liu, Hongyan Li, Pan Wang · 2025
Read Exploring HSP90α and hs-CRP using AI models to predict prognosis in advanced hepatocellular carcinoma treated with PD-1 inhibitors and targeted therapy by Zhen-Ying Wu, Xueting Li, Lu Yang, Yuhui Shi, Xianguo Liu, Lianbin Wen, Yanqiong Song, Wanyun Du, Yulin Tu, Qian Wei, Junqi Liu, Hongyan Li, Pan Wang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12741144.txt.
Description
The authors pair two blood markers with machine learning to forecast survival in advanced liver cancer under immune therapy. Their 2025 study reviews six hundred forty-four patients treated at three Chinese hospitals from 2016 to 2023. All got PD-1 blocking drugs plus targeted therapy.
High levels of a heat-shock protein cut median survival from about twenty-one months to under eight. High inflammation marker levels also halved survival. Selection methods kept seven factors, from age to tumor count and vein invasion. Five learning models were built, and a random survival forest scored best. Its accuracy held in a held-out group across six, twelve, and eighteen months. The authors offer the tool for treatment planning talks.
Catalog record
| CREATOR | Zhen-Ying Wu, Xueting Li, Lu Yang, Yuhui Shi, Xianguo Liu, Lianbin Wen, Yanqiong Song, Wanyun Du, Yulin Tu, Qian Wei, Junqi Liu, Hongyan Li, Pan Wang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |